Zobrazeno 1 - 10
of 317
pro vyhledávání: '"Thomas F Imperiale"'
Autor:
Thomas F. Imperiale, Zubin D. Gagrat, Martin Krockenberger, Kyle Porter, Emily Ziegler, Christine M. Leduc, Michael B. Matter, Marilyn C. Olson, Paul J. Limburg
Publikováno v:
Gastro Hep Advances, Vol 3, Iss 6, Pp 740-748 (2024)
Background and Aims: The multitarget stool DNA (mt-sDNA) assay is a noninvasive average-risk colorectal cancer (CRC) screening test. A new biomarker panel was developed for a next-generation test to improve specificity while maintaining/increasing se
Externí odkaz:
https://doaj.org/article/65d575a8ee844d8ab46a22e9cf6bbdce
Autor:
Derek W. Ebner, MD, David Rushlow, MD, Joshua Mou, MD, Kyle Porter, MAS, Lila J. Finney Rutten, MPH, PhD, Paul Limburg, MD, Feyza Sancar, PhD, Thomas F. Imperiale, MD
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 7, Iss 4, Pp 320-326 (2023)
Objective: To evaluate the effect of hemorrhoids on noninvasive stool test performance for colorectal cancer (CRC) screening. Patients and Methods: We conducted a retrospective cohort study of test characteristics for the fecal immunochemical test (F
Externí odkaz:
https://doaj.org/article/6964387b6db24b01b3f3da0d1797cb3c
Autor:
Jingwu Xie, Chi Mai Nguyen, Anita Turk, Hongmei Nan, Thomas F. Imperiale, Michael House, Kun Huang, Jing Su
Publikováno v:
Genes and Diseases, Vol 10, Iss 4, Pp 1172-1174 (2023)
Externí odkaz:
https://doaj.org/article/1431ce9f9c324a3b9e78bf95ce370a27
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Medical evidence from more recent observational studies may significantly alter our understanding of disease incidence and progression, and would require recalibration of existing computational and predictive disease models. Howev
Externí odkaz:
https://doaj.org/article/af729e810fd3424e9938a42328f238b4
Publikováno v:
BMC Family Practice, Vol 21, Iss 1, Pp 1-8 (2020)
Abstract Background Despite proven effectiveness of colorectal cancer (CRC) screening, at least 35% of screen-eligible adults are not current with screening. Decision aids and risk prediction tools may help increase uptake, adherence, and efficiency
Externí odkaz:
https://doaj.org/article/98665daf5c034f118d33e6f4d8f486a5
Autor:
Khoa A. Nguyen, Himalaya Patel, David A. Haggstrom, Alan J. Zillich, Thomas F. Imperiale, Alissa L. Russ
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 19, Iss 1, Pp 1-13 (2019)
Abstract Background A pharmacogenomic clinical decision support tool (PGx-CDS) for thiopurine medications can help physicians incorporate pharmacogenomic results into prescribing decisions by providing up-to-date, real-time decision support. However,
Externí odkaz:
https://doaj.org/article/972512724224490db0f3003e14ad2baa
Publikováno v:
Eur J Cancer Prev
BACKGROUND Models estimating risk for advanced proximal colorectal neoplasia (APN) may be used to select colorectal cancer (CRC) screening test, either prior to knowing distal colorectal findings or afterward. Current models have only fair discrimina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a5e3cec5213a3f49cb63fd13ad466dc
https://pubmed.ncbi.nlm.nih.gov/34545024
https://pubmed.ncbi.nlm.nih.gov/34545024
Autor:
Thomas F. Imperiale, Laura J. Myers, Barry C. Barker, Jason Larson, Timothy E. Stump, Joanne K. Daggy
Publikováno v:
Cancer Prevention Research.
Identifying risk factors for early onset colorectal cancer (EOCRC) could help reverse its rising incidence through risk factor reduction and/or early screening. We sought to identify EOCRC risk factors that could be used for decisions about early scr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3dbc6177ac6d119caf0c20e73cdb8629
https://doi.org/10.1158/1940-6207.capr-22-0506
https://doi.org/10.1158/1940-6207.capr-22-0506
Autor:
Barry M. Berger, Anas Daghestani, Seth Sweetser, Paul J. Limburg, Folasade P. May, Steven H. Itzkowitz, Debbie Jakubowski, Tara N. Marti, Philip T. Lavin, Thomas F. Imperiale
Data supporting the clinical utility of multi-target stool DNA (mt-sDNA) at the guideline-recommended 3-year interval have not been reported.Between April 2015 and July 2016, candidates for colorectal cancer screening whose providers prescribed the m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95953a30385c3869212bfea9ba839cc3
https://doi.org/10.1158/1940-6207.c.6547907.v1
https://doi.org/10.1158/1940-6207.c.6547907.v1
Autor:
Barry M. Berger, Anas Daghestani, Seth Sweetser, Paul J. Limburg, Folasade P. May, Steven H. Itzkowitz, Debbie Jakubowski, Tara N. Marti, Philip T. Lavin, Thomas F. Imperiale
Supplemental Table S1: Distribution of colorectal lesions among subjects at baseline (T0) and year 3 (T3). Supplemental Table S2: Study subject accountability in the baseline negative population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::491bf66db83c3e8fc84ba36740d632f1
https://doi.org/10.1158/1940-6207.22535663
https://doi.org/10.1158/1940-6207.22535663